In summary, while multiple pharmacological approaches aimed against the IGF axis have been actively investigated for the treatment of PDTCs and ATCs, further biological studies and additional compounds and/or pharmacological strategies will be required to significantly improve the outcome of these aggressive forms of thyroid cancer. This evidence concerns the gene IGF1 and thyroid cancer.